Prestige Consumer Healthcare Inc. (PBH)
NYSE • Healthcare
Last close at September 9, 2026 at 20:00 UTC
Metrics Over Time
Where the Money Goes
Q2 2026In plain terms: out of every $100 in revenue, Prestige Consumer Healthcare Inc. keeps $11 as net profit.
Fundamentals & Financials
TTM is calculated as the sum of the four most recently completed quarters. This is a standard approach when monthly or real-time data is not available.
Income Statement
Balance Sheet
Financial Highlights
Dividends History
Split History
Earnings
Nov 5
in 56 daysQ4 2026% — EPS deviation from the forecast (beat / miss); quarters without a forecast show the reported EPS
Prestige Consumer Healthcare beat estimates on both revenue and adjusted EPS in the first fiscal quarter of 2027, reported on Aug. 6, as revenue rose 6.5% to about $265.7 million and came in above the $250.3 million consensus by 6.1%, with gross margin near 51% and operating margin about 20%. Adjusted EPS of $0.98 topped the $0.89 estimate by 9.6% and was up from $0.95 a year ago, while net income fell 38.5% to about $29.2 million from $47.5 million a year earlier. Operating cash flow came in at about $70.8 million, and the company repurchased about $2.7 million of stock during the period. Next-period consensus calls for EPS of $1.06 on revenue of $293.2 million.
About Prestige Consumer Healthcare Inc.
Prestige Consumer Healthcare Inc. sells over-the-counter consumer health products in the healthcare sector and trades on the NYSE under PBH. Its portfolio includes branded remedies for pain relief, infant care, sore throat and cough symptoms, eye care, digestive needs, and women's health, and it generated $1.1 billion of revenue in FY2026.
Today's Snapshot
PBH ended yesterday 2.2% down at 48.70.
Trading Volume
Above 10d avg 415.7K
471.8K
vs S&P 500 Today
Underperforming Market
-1.71%
Updated: September 10, 2026 at 12:04 UTC
Technical Indicators
All signalsHide signals
- EMA (5 indicators)$51.12 - $56.07Sell
- RSI (14)38.81Neutral
- Stochastic %K (14, 3, 3)22.92Neutral
- MACD Level (12, 26)-0.06Sell
Peers & Related Assets
Get premium market insights delivered directly to your inbox.